灯盏花素联合依达拉奉治疗缺血性脑卒中的临床疗效及对患者神经功能缺损和生活质量的影响
Clinical effect of edaravone and breviscapine injection and its influence on neurologic impairment and life quality of patients with ischemic stroke
-
摘要: 目的 探讨灯盏花素联合依达拉奉治疗缺血性脑卒中的临床疗效以及对患者神经功能的影响.方法 选取符合标准的148例缺血性脑卒中患者,随机分成观察组74例与对照组74例,观察组采用灯盏花素联合依达拉奉进行治疗,对照组仅使用依达拉奉进行治疗.治疗2周后,比较2组患者疗效、神经功能变化以及生活质量.结果 治疗后,观察组患者总效率为94.59%,显著性高于对照组的81.08% (P<0.05).观察组NIHSS评分显著性低于对照组(P<0.05).治疗后第7天,观察组患者血清NSE、S-100β以及MMP-9水平均显著低于对照组(P<0.05);第14天,观察组患者MMP-9水平显著低于对照组(P<0.05),SF-36生活质量评分显著性优于对照组(P<0.05).结论 灯盏花素联合依达拉奉治疗缺血性脑卒中疗效肯定,值得临床推广.Abstract: Objective To explore clinical effect of edaravone and breviscapine injection and its influence on neurologic impairment and life quality of patients with ischemic stroke.Methods A total of 148 patients were randomly divided into observation group (74 cases) and control group (74 cases).Patients in observation group were treated with edaravone and breviscapine injection,while those in the control group were treated with edaravone injection.The clinical efficacy,neurologic impairment and quality of life were compared.Results After treatment,the total response rate was 94.59% in observation group,which was significantly higher than 81.08% in the control group (P <0.05).The NIHSS scores of observation group were significantly better than that of control group (P <0.05).The serum NSE,S-100β and MMP-9 levels of observation group after 7 d treatment were significantly lower than that of the control group (P < 0.05),and the serum MMP-9 level of observation group after 14 d was significantly lower than that of the control group (P < 0.05).The SF36 quality of life scores of observation group were significantly better than that of control group (P <0.05).Conclusion The treatment of edaravone and breviscapine for patients with ischemic stroke has an obvious curative effect,and it is worthy of further promotion in clinic.